Deep-brain Probe and Method for Recording and Stimulating Brain Activity

A probe suitable for deep-brain recording and stimulation is provided. The probe comprises a wire bundle that includes a plurality of wires, an integrated circuit having a plurality of electrodes, and an interposer that joins the wire bundle and the integrated circuit such that each of the plurality of electrodes is electrically connected with a different wire of the plurality of wires. 1. A deep-brain probe comprising: a core that is electrically conductive;', 'an electrical insulator that surrounds the core along the length of the wire; and', 'an electrode that is electrical-insulator-free;, 'a wire bundle comprising a first plurality of wires that are arranged in a first two-dimensional arrangement, wherein each of the first plurality of wires has a first end and a second end, and wherein each of the first plurality of wires includeswherein the wire bundle has a first portion in which the first plurality of wires is mechanically joined together to collectively define a stalk, the first end of each wire of the plurality thereof terminating at a first surface of the stalk; andwherein the wire bundle has a second portion in which each wire of the first plurality thereof is unrestrained, the second end and the electrode of each wire of the plurality thereof being in the second portion; anda first integrated circuit comprising a plurality of bond pads that is arranged in a second two-dimensional arrangement;wherein the wire bundle and the first integrated circuit are arranged such that each of the plurality of bond pads is electrically connected with one or more wires of the first plurality thereof, and wherein each electrical connection is established via an elastically deformable element.2. The probe of further comprising an interposer that includes:a body having a first surface and a second surface, the body comprising a first material that is an electrical insulator, and the body being compressible; anda plurality of conductors that extend through the body from ...

Treatment of hr deficient cancer

Analysis of HLA alleles in tumors and uses thereof

本发明涉及测定受试者的肿瘤中HLA等位基因是否丧失的方法，其中所述方法包括测定所述肿瘤中所述HLA等位基因的特异性拷贝数的步骤。本发明还涉及用于治疗受试者的癌症的方法，其包括靶向新抗原(neoantigen)，所述新抗原预测由HLA等位基因编码的HLA分子呈递，所述HLA等位基因已经测定为在所述受试者的肿瘤中尚未丧失。

Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells

This invention relates to the expansion of non-haematopoietic tissue-resident γδ T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and/or interleukin-15 (IL-15)and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident γδ T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident γδ T cells and uses thereof.

Composition for culture of pluripotent stem cells

The present invention relates to a chemically defined or minimal cell medium for culturing pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells. The said medium may consistof the followingcomponents: a base medium, IGF1, a TGF-βfamilymember and a glutamine supplement.The inventionalso relates to methods and uses involving the cell medium.

Embedded wireless benchmarking systems and methods

Systems and methods for measuring the performance of a provider of communications service are described. A plurality of mobile communications devices measure average power received, signal to noise ratio, voice quality, blocked and dropped calls, or any combinations of such measurements. The device may also receive a set of data identifying the location of the device. The device may transmit one or more communications signals to a server computer system with such measurements and location data. The measurements and location data may be stored in a database, and new data may be created and transmitted illustrating a subset of the measurements and location data.

Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells

Expansion of non-haematopoietic tissue-resident γδ T cells and uses of these cells

This invention relates to the expansion of non-haematopoietic tissue-resident y6 T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the 5 presence of interleukin-2 (IL-2) and/or interleukin-15 (IL-15)and the absence of TCR activation or co stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non haematopoietic tissue-resident y 6 T cell expansion are provided, as well as populations of non haematopoietic tissue-resident y 6 T cells and uses thereof.

Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells

Assays for nucleoside diphosphates and triphosphates

Nucleoside diphosphates (NDPs) are detected or measured by following the dephosphorylation of the phosphoenzyme form of nucleoside diphosphate kinase (NDPK), and nucleoside triphosphates (NTPs) are detected or measured by following the phosphorylation of NDPK to its phosphoenozyme form. A typical process involves (a) causing NDP in sample to bind to NDPK phosphoenzyme, or causing NTP in sample to phosphorylate NDPK and (b) detecting a change in a charateristic of the enzyme which differs between its phosphorylated and unphosphorylated forms. This may be aided by labelling the enzyme. Quantitative data can be obtained. Both in vivo and in vitro measurements can be made.

Method to assess suitability for cancer immunotherapy

The present invention relates to a method for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention, said method comprising analysing in a sample isolated from said subject the expressed frameshift indel mutational burden.

Biotinylation bovine gamma globulin-streptavidin ELISA (enzyme linked immunosorbent assay) plate and preparation method thereof

本发明提供一种生物素化牛丙种球蛋白-链霉亲和素酶标板，包括聚苯乙烯微孔板。所述聚苯乙烯微孔板的每个微孔内预先包被有1.5-3.0微克生物素标记的牛丙种球蛋白、2.7-3.3微克链霉亲和素，并用封闭溶液封闭。使用本发明的酶标板，可不直接包被捕获抗体，而是将捕获抗体标记生物素，利用生物素-亲和素系统将捕获抗体在与待检抗原反应的过程中，与固相材料(微孔板)结合，从而达到固相吸附和分离的目的，解决了传统直接包被捕获抗体所带来的抗体利用率低，包被量不能满足要求，减缓反应到达平衡时间的缺陷。

Composition for culture of pluripotent stem cells

The present invention relates to a chemically defined or minimal cell medium for culturing pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells. The said medium may consistof the followingcomponents: a base medium, IGF1, a TGF-ßfamilymember and a glutamine supplement.The inventionalso relates to methods and uses involving the cell medium.

Single-baffle enzyme linked immunosorbent assay (ELISA) plate

本实用新型提供一种单隔板酶标板，包括外框和板条，其特征在于：所述外框包括隔板和若干板条固定槽，板条包括固定件和若干样品杯，所述固定件对应嵌入板条固定槽中。本实用新型的有益效果是在实验过程中更换样品杯更加方便，具有结构简单，加工成本低的优点。

A kind of public bicycles

本实用新型涉及无轨陆用车辆技术领域，具体是一种公共自行车，车架上设有中控台和发电与助力系统，传动装置包括位于车架下部的牙盘外壳，牙盘外壳的左右两侧分别通过一曲柄连接左、右脚踏板，牙盘外壳内设有牙盘，牙盘外壳与车架内部相通，在车架内部、位于车架与后叉的连接处设有中间轴，中间轴上同轴设有中间轴单向自由飞轮、中间轴固定齿轮，在后叉与后轮的连接处设有后连接轴，后连接轴上设有后轮固定齿轮，牙盘与中间轴单向自由飞轮之间、中间轴固定齿轮与后轮固定齿轮之间分别通过一传动链连接。本实用新型具有智能化特点，带有GPS卫星定位、蓝牙开锁关锁、防盗报警、夜晚车轮彩色动画影像显示等功能。

Reaction plate without measuring light transmittance

本实用新型提供一种无需测定透光率的反应板，包括外框和样品杯板条，其特征在于：所述外框包括若干方形插槽，托盘和托盘上的若干圆形插槽，样品杯板条包括固定件和若干不透明样品杯，所述固定件对应嵌入方形插槽中，所述不透明样品杯对应嵌入圆形插槽中，所述不透明样品杯为底面为圆形的倒圆锥体。本实用新型的有益效果是在运用高通量化学发光免疫分析方法进行实验时，使用该反应板可大幅降低实验成本，并且无需测定透光率，有效提高了检测灵敏度和准确度。

Fusion proteins of ctl antigens for treating melanoma

There are disclosed inter alia fusion proteins and nucleic acids encoding said fusion proteins which are useful in the treatment and prevention of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

Apparatus, system, and method for determining demographic information to facilitate mobile application user engagement

提供一种用于确定人口统计信息以促进移动应用用户参与远程计算环境的计算机实现的方法。该方法包括捕获用户的社交媒体数据并将其编译到第一数据库中；通过检测用户的人口统计属性的显式标识来处理社交媒体数据；对于一个类别的每个显式标识的人口统计属性设置100％的概率值；对于未针对该类别显式标识的每个人口统计属性设置0％的概率值；通过使用显式标识的人口统计属性搜索辅助数据库来确定第二类别的派生属性；使用训练数据训练神经网络，训练数据包括显式标识的人口统计属性及其关联的概率值，以及派生属性及其关联的概率值；向神经网络输入第二用户的社交媒体数据；通过神经网络预测第二用户的人口统计属性。

Novel cancer antigens and methods

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly non small cell lung cancer, especially lung squamous cell carcinoma and melanoma, especially cutaneous melanoma.

Method and system for reducing memory allocation requests

A computer method and system for allocating memory for a plurality of software routines. Before execution of the software routines, a collective buffer is allocated. Each software routine is assigned an offset within the collective buffer. Each software routine may then use the portion of the collective buffer starting at its offset as its dynamically allocated work space. To allocate the collective buffer, a collective buffer size is first determined which is sufficient to satisfy the total dynamic memory requirements of the software routines. In determining the collective buffer size, the size of a software routine buffer required by each software routine is accumulated into the collective buffer size. As each software routine buffer size requirement is accumulated, the interim total is stored as the offset for the next software routine. When the last software routine buffer size requirement is accumulated, the total indicates the collective buffer size. A collective buffer of the collective buffer size is then allocated. When the software routines are executed, each software routine uses a portion of the collective buffer referenced by its assigned offset. When all the software routines complete execution, the collective buffer may then be deallocated. In a preferred embodiment, the memory is allocated to a software system having a layered architecture including an application program and a device driver comprising a plurality of component device drivers.

Hair-planted spray nozzle

本实用新型公开了一种植毛花洒，具体为一种植毛水喷头，属于有多个出口孔的喷头，或刷毛固定在刷体上的刷子。本实用新型包括中空手柄一端连接的柔性水管，手柄另一端形成的中空喷头，喷头的一侧面上形成有点阵分布的出水孔，而在形成有出水孔的喷头上还形成有刷毛。这样设计的本实用新型集刷毛和水喷头于一体，清洁实验动物或宠物的笼舍时，喷头的出水孔喷淋出水的同时，利用喷头上刷毛对笼舍进行喷淋冲洗和松动硬结的残留物。降低了饲养人员的劳动强度，大大提高了清洁工作效率。

Methods for detecting molecules in a sample

The present invention relates to a method for detecting molecules. The method employs: at least two primary antibodies, wherein the first primary antibody binds to a first site on a molecule and the second primary antibody binds to a second site on a molecule, wherein the second site is different from the first site and wherein the first and second primary antibodies are immunologically distinct; at least two secondary antibodies, wherein the first secondary antibody is labelled with a fluorescence resonance energy transfer (FRET) donor and binds to the first primary antibody; and the second secondary antibody is conjugated or fused to an enzyme and binds the second primary antibody, wherein the first secondary antibody does not bind the second primary antibody and the second secondary antibody does not bind the first primary antibody; a conjugate comprising a FRET acceptor and a substrate specific for the enzyme, wherein when the substrate reacts with the enzyme, an activated conjugate forms, which activated conjugate binds to electron rich moieties on a molecular surface adjacent to the enzyme; wherein the method comprises: contacting a sample with the at least two primary antibodies; contacting the sample with the at least two secondary antibodies; performing a wash step; contacting the sample with the conjugate; and detecting any FRET signal generated by the FRET acceptor.

Vcp inhibitors and uses thereof for treatment

VCP INHIBITORS AND USES THEREOF FOR TREATMENT The present invention relates to inhibitors of Valosin-containing protein (VCP or p97) and the use thereof in the treatment or prevention of diseases such as amyotrophic lateral sclerosis (ALS). In particular the present invention provides VCP inhibitors for use in a method of treating or preventing ALS wherein the subject has been identified as not having a disease-causing genetic mutation in a VCP gene (non-VCP-associated ALS). The invention also relates to methods of identifying a patient as not having a disease-causing mutation in a VCP gene.

Cytosolic delivery

本発明は、抗原の交差提示（ＸＰ）を促進させることができるキメラ受容体、およびそれを行う方法に関する。

Zinc complexes and their uses

A zinc complex of a compound where the zinc complex is either a complex of JBIR-141 and a zinc ion and has the chemical formula C 31 H 48 N 6 O 11 Zn, or where the zinc complex is a complex of JBIR-142 and a zinc ion and has the chemical formula C 31 H 48 N 6 O 12 Zn.

Methods and systems for tumour monitoring

Food intolerant serological specificity IgG detection kit and preparation method thereof

本发明提供一种食物不耐受血清特异性IgG检测试剂盒及其制备方法。所述试剂盒包括：(1)预包被生物素化牛血清白蛋白-链霉亲和素的酶标反应板、(2)生物素标记的食物变应原、(3)生物素标记抗人IgG抗体、(4)人IgG标准品、(5)阳性质控血清、(6)酶标记抗人IgG抗体、(7)常规酶标清洗液、(8)显色液A、(9)显示液B和(10)终止液。本发明的试剂盒使得检测人员可以根据被检者的具体情况灵活选择所需检测的食物变应原，将生物素标记变应原和待测血清同时加入微孔板内，实现即时包被，并且包被和检测过程同步进行，大大降低了检测成本，提高了检测灵活性，实现个性化检测。

Combination therapy for treating abnormal cell growth

The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).

Analysis of hla alleles transcriptional deregulation

Methods for determining whether an HLA gene has deregulated expression in a sample from a subject. The methods comprise obtaining RNA sequence data from the sample; obtaining a reference sequence that is specific to one or more HLA alleles identified to be present in the subject; and aligning the RNA sequence data from the sample to the genomic reference sequence and determining whether one or more HLA alleles in the reference sequence have deregulated expression based on one or more metrics derived from the aligned RNA sequence data at mismatch positions between homologous alleles and/or at one or more non- canonical splice junctions in the reference sequence, and one or more corresponding reference values. Methods of providing or identifying a therapy, as well as prognostic methods are also described, as well as related systems and products.

Methods of treatment of gnaq and gna11 driven disease

The present invention relates to novel compositions and methods of treating clinical conditions arising from GNAQ and GNA11 somatic mutations including cancer, Sturge-Weber syndrome (SWS), Phakomatosis Pigmentovascularis (PPV), Extensive Dermal Melanocytosis (EDM) and congenital hemangiomas (including rapidly involuting congenital hemangioma (RICH), partially involuting congenital hemangioma (PICH) and non-involuting congenital hemangioma (NICH)).

Immunoconjugate

The present invention provides immunoconjugates comprising an antigen and an F-actin-binding moiety. These immunoconjugates promote the presentation of antigens. The invention also provides vaccines that comprise or encode conjugates that allow antigens to be presented to the immune system. Related medical uses and methods of eliciting an immune response are also provided.

Bispecific binding agent

The present invention relates to bispecific binding agents comprising an F-actin binding moiety and an Fc domain for use in medicine, which allows for simultaneous binding of an Fc receptor and F-actin. This allows necrotic cell antigens to be presented to the immune system. The invention also provides bispecific binding agents and methods of using the agent to identify a tumour antigen.

Thymic constructs and uses thereof

The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing an acellular scaffold; (ii) seeding the acellular scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce said construct. The thymic epithelial cells are preferably CD49f+ and may also be VIM+, TE-7+ and/or CD90+. The invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.

测试容器架

测试容器(2)支架包括孔(6)，这些孔用于容纳测试容器，每个孔具有第一侧和与第一侧相对的第二侧；永磁体(4、M1‑M6)；以及致动器(16)，该制动器在永磁体和孔(6)之间施加相对移动，以在第一配置和第二配置之间切换。对于给定的孔(6)：在第一配置和第二配置中的一者中，永磁体中的一个被定位为与该孔的第一侧邻近，在第一配置和第二配置中的另一者中，永磁体中的不同的一个永磁体被定位为与该孔的第二侧邻近。这对于涉及放置在容器中的磁珠的许多实验室实验是有用的。

Techniques for detecting minimum residual disease

The present disclosure describes techniques for determining an indication of minimum residual disease (MRD) in a subject. The indication of MRD may be determined based on sequencing data from a biological sample of the subject. These techniques are performed in part by determining sequencing error and an indication MRD from the same biological sample using the same set of sequencing data.

Optical measurement apparatuses for use with a cutting apparatus

There is described an apparatus for characterising a thickness of one or more slices obtained from an outer surface of a sample using a microtome apparatus, the apparatus comprising a detector configured to receive optical signals reflected and / or scattered from at least first and second portions of the surface of a sample or sample holder assembly associated with the microtome apparatus, and provide an output indicative of at least one characteristic of the received optical signals; and a controller configured to: determine first information indicative of a position of a first surface portion of a sample or a sample holder assembly of the microtome apparatus prior to the obtaining of one or more slices from the outer surface of a sample using a blade assembly associated with the microtome apparatus, wherein the first information is determined based on a first output of the detector associated with optical signals received from the first surface portion of the sample or sample holder assembly, determine second information indicative of a position of a second surface portion of the sample or sample holder assembly of the microtome apparatus subsequent to the obtaining of one or more slices from the outer surface of the sample using the blade assembly associated with the microtome apparatus, wherein the second information is determined based on a second output of the detector associated with optical signals received from the second surface portion of the sample or sample holder assembly; and determine a thickness of at least one of the one or more slices obtained from the sample using the blade assembly of the microtome, based on the first and second information; along with corresponding methods and computer programs. Further described is an apparatus for characterising an orientation of an external surface of a sample or sample holder associated with a microtome apparatus, the apparatus comprising: a first detector configured to receive optical signals reflected ...

网络环境中的消息传递选择系统

个性化消息传递系统的用户可能会遭遇消息疲劳，从而降低消息对预期接收者的效力。消息疲劳可能会导致计算资源和带宽的浪费，因为通过网络传输到用户客户端设备的消息在客户端设备上没有起作用。对于涉及期望的用户交互和响应的应用程序，个性化消息传递可以是实现用户参与度目标的工具。本文呈现的系统和方法可以解决个性化消息传递的若干技术挑战。

确保使用数字疗法的疾病和障碍的治疗中的数据安全性的系统和方法

一种方法，包括通过网络从与具有用于治疗潜在疾病或障碍的激活的数字治疗处方的患者相关联的患者设备接收患者生成的事件数据。患者生成的事件数据由患者设备加密，并且包括与激活的数字治疗处方相关的至少一个带时间戳的事件。响应于接收到患者生成的事件数据，该方法包括解密、匿名化和将匿名化的患者生成的事件数据存储在存储器硬件上。该方法还包括通过网络从医疗保健提供者(HCP)系统接收请求患者生成的事件数据并包括认证令牌的患者记录请求。响应于接收到该患者记录请求，该方法包括使用认证令牌从存储器硬件检索和加密匿名化的患者生成的事件数据。该方法还包括将经加密的患者生成的事件数据传送到HCP系统。

A safety device

Sensor means for monitoring the awareness status of an individual within a monitored environment ( 50 ) comprising means ( 55 ) for determining the attainment of at least one predetermined condition identifying the requirement for the awareness of an individual to be monitored, and operative to trigger an alarm ( 70 ), means ( 15 ) operable by the monitored individual for inhibiting the operation of the alarm, and delay means for delaying the triggering of the alarm ( 70 ) for a predetermined period after the attainment of the said predetermined condition.

Methods of treatment of melanocytic disease

Method, solution and kit for preparing a tissue sample for 3d imaging

The present invention relates to a solution for the preparation of a tissue sample for the purpose of three dimensional (3D) imaging. The invention also relates to methods and uses involving the solution.

网络环境中的消息传递选择系统

个性化消息传递系统的用户可能会遭遇消息疲劳，从而降低消息对预期接收者的效力。消息疲劳可能会导致计算资源和带宽的浪费，因为通过网络传输到用户客户端设备的消息在客户端设备上没有起作用。对于涉及期望的用户交互和响应的应用程序，个性化消息传递可以是实现用户参与度目标的工具。本文呈现的系统和方法可以解决个性化消息传递的若干技术挑战。

Thymic epithelial stem cells

The present invention relates to a newly identified population of thymic epithelial stem cells, methods for their isolation, culture and differentiation, and uses of the cells, in particular their use in therapy, creation of therapeutic thymic constructs and drug screening.

Μεθοδοι ανιχνευσης μοριων σε ενα δειγμα

Η παρούσα εφεύρεση αφορά μία μέθοδο για την ανίχνευση μορίων. Η μέθοδος χρησιμοποιεί: τουλάχιστον δύο πρωτεύοντα αντισώματα, όπου το πρώτο πρωτεύον αντίσωμα δεσμεύεται σε μία πρώτη θέση σε ένα μόριο και το δεύτερο πρωτεύον αντίσωμα δεσμεύεται σε μία δεύτερη θέση σε ένα μόριο, όπου η δεύτερη θέση είναι διαφορετική από την πρώτη θέση και όπου το πρώτο και δεύτερο πρωτεύον αντίσωμα είναι ανοσολογικά διακριτά• τουλάχιστον δύο δευτερεύοντα αντισώματα, όπου το πρώτο δευτερεύον αντίσωμα είναι επισημασμένο με έναν δότη μεταφοράς ενέργειας συντονισμού φθορισμού (FRET) και δεσμεύεται με το πρώτο πρωτεύον αντίσωμα• και το δεύτερο δευτερεύον αντίσωμα είναι συζευγμένο ή συγχωνευμένο με ένα ένζυμο και δεσμεύει το δεύτερο πρωτεύον αντίσωμα, όπου το πρώτο δευτερεύον αντίσωμα δεν δεσμεύει το δεύτερο πρωτεύον αντίσωμα και το δεύτερο δευτερεύον αντίσωμα δεν δεσμεύει το πρώτο πρωτεύον αντίσωμα• ένα σύζευγμα που περιλαμβάνει έναν δέκτη FRET και ένα υπόστρωμα ειδικό για το ένζυμο, όπου όταν το υπόστρωμα αντιδρά με το ένζυμο, σχηματίζεται ένα ενεργοποιημένο σύζευγμα, το οποίο ενεργοποιημένο σύζευγμα δεσμεύεται με τμήματα πλούσια σε ηλεκτρόνια σε μία μοριακή επιφάνεια γειτονικά προς το ένζυμο• όπου η μέθοδος περιλαμβάνει: επαφή ενός δείγματος με τα τουλάχιστον δύο πρωτεύοντα αντισώματα• επαφή του δείγματος με τα τουλάχιστον δύο δευτερεύοντα αντισώματα• εκτέλεση ενός βήματος πλύσης• επαφή του δείγματος με το σύζευγμα• και ανίχνευση οποιουδήποτε σήματος FRET που παράγεται από τον δέκτη FRET.

Methods and systems for tumour monitoring

The present invention provides a computer-implemented method for estimating the cancer cell fraction (CCF) of at least one tumour-specific mutation in a subject. Also provided are related methods for monitoring the clonal dynamics of a tumour, monitoring a treatment of the tumour and methods for treating a subject having a cancer, as well as systems for implementing the methods of the invention.

Determination of lymphocyte abundance in mixed samples

Methods for determining the fraction of lymphocytes in a mixed sample comprising genomic material from multiple cell types are described. The methods comprise obtaining a read depth profile for the sample along a predetermined genomic region of interest including at least a portion of a genomic locus that undergoes VDJ recombination; obtaining a plurality of read depth ratios (ri) by normalising the read depths by reference to a baseline read depth derived from a subset of the region of interest; obtaining a summarised read depth ratio value (rVDJ) for a subset of the region of interest that is likely to be deleted through VDJ recombination; and determining the fraction of lymphocytes (f) in the sample as a function of the summarised read depth ratio value (rVDJ). Methods of providing a diagnosis or prognosis based on the lymphocyte fraction are also described, as well as related systems and products.

Optical measurement apparatuses for use with a cutting apparatus

Apparatus for characterising thickness of slices obtained from a sample 210 using a microtome, comprises; detector 250 configured to receive optical signals reflected and/or scattered from at least first and second portions of the surface 211 of a sample or sample holder; controller configured to: determine first information indicative of a position of the first surface portion prior to obtaining slices using a blade 230, the first information is determined based on a first detector output, determine second information indicative of a position of the second surface portion subsequent to obtaining slices, the second information is determined based on a second detector output; and determine slice thickness based on the first and second information. Apparatus for characterising an orientation of an external surface of a sample or sample holder associated with a microtome is also disclosed. A first detector is configured to receive optical signals reflected and/or scattered from each of a plurality of surface portions of the sample or sample holder. A controller is configured to determine first information indicative of a respective position of each of the plurality of surface portions and determine an orientation of the surface based on the first information.

Immunotherapy

Gelsolin inhibitors are provided for use in treating diseases such as infectious diseases and cancer. Prognostic methods and methods for screening for gelsolin inhibitors are also provided.

Thymic epithelial stem cells

Accessible Keyboard for Mobile Devices and Tablets

An accessible virtual keyboard provided as a computer-readable medium including instructions, that when executed by a controller in communication with a user interface, cause the controller to: in response to a request from a running application, display a keyboard including selectable cluster keys via the user interface, wherein each cluster key is associated with a character set including two or more characters, wherein each displayed cluster key includes each character of the character set displayed within a boundary; in response to a selection of one of the cluster keys, display selectable individual keys of the character set associated with the selected cluster key via the user interface, wherein each individual key is associated with a single character of the character set associated with the selected cluster key; and, in response to a selection of one of the individual keys, provide the associated character as an input to the running application.

Combination therapy for treating abnormal cell growth

新的癌抗原和方法

尤其公开了可用于治疗、预防和诊断癌症、具体是黑素瘤、尤其是皮肤黑素瘤和葡萄膜黑素瘤的多肽和编码所述多肽的核酸。

用于资产分配的候选者的可量化分类的系统和方法

资产向量分析(AVA)计算设备从数据库中取得与多个个体投资者以及该多个投资者的过去投资活动有关的投资者数据。该设备针对每个个体投资者计算投资者得分，并向个体投资者中的至少一些发送资产公开发行的通知。该设备从个体投资者接收响应，该响应指示相应投资者愿意在公开发行上投资的金额。该设备确定公开发行中对于个体投资者可用的资产总额。该设备至少部分地基于个体投资者的投资者得分来分配对于个体投资者可用的资产总额的一部分。

Cytosolic delivery

The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.

Cytosolic delivery

The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.

胞质溶胶递送

本发明涉及能够促进抗原的交叉呈递(XP)的嵌合受体及其实施方法。

Cytosolic delivery

The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.

Cytosolic delivery

The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.

Cytosolic delivery

The present invention relates to chimeric receptors capable of facilitating cross-presentation (XP) of antigens, and methods of doing the same.

Multimodal needle

Targets for treatment of alt-positive cancers

Targets for treatment of alt-positive cancers

用于治疗异常细胞生长的组合疗法

本公开涉及双重RAF/MEK抑制剂与抗PD‑1抗体或抗PD‑L1抗体和KRAS G12C抑制剂以及任选的FAK抑制剂组合的方法、组合物和口服剂型，用于治疗异常细胞生长(例如癌症)。

Combination therapy for treating abnormal cell growth

The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).

Microfluidic device

Analysis of HLA alleles transcriptional deregulation

Methods of treatment of intestinal infections

Bispecific binding agent

Bispecific binding agent

Improvements relating to apparatus for rectifying alternating electric current

Method of predicting survival rates for cancer patients

The present invention provides a method for providing a prognosis for a subject with lung cancer, the method comprising: (a) contacting a biological sample from the subject with reagents that specifically bind to each member of a panel of biomarkers comprising ANLN, ASPM, CDCA4, ERRFI1, FURIN, GOLGA8A, ITGA6, JAG1, LRP12, MAFF, MRPS17, PLK1, PNP, PPP1 R13L, PRKCA, PTTG1, PYGB, RPP25, SCPEP1, SLC46A3, SNX7, TPBG, XBP1; (b) determining a riskscore of the subject based on the nucleic acid levels of expression of the biomarkers in the samples; and (c) providing a prognosis for the lung cancer based on the risk score of the subject.

Novel reprogramming activators and methods

Techniques for detecting minimum residual disease

Test receptacle rack

A test receptacle (2) rack comprises apertures (6) for receiving test receptacles, each aperture having a first side and a second side opposite the first side; permanent magnets (4, M1-M6), and an (actuator 16) to impart relative motion between the permanent magnets and the apertures (6) to switch between a first configuration and a second configuration. For a given aperture (6): in one of the first configuration and the second configuration, one of the permanent magnets is positioned adjacent to the first side of the aperture, in the other of the first configuration and the second configuration, a different one of the permanent magnets is positioned adjacent to the second side of the aperture. This is useful for many lab experiments involving magnetic beads placed in receptacles.

Test receptacle rack

A test receptacle (2) rack comprises apertures (6) for receiving test receptacles, each aperture having a first side and a second side opposite the first side; permanent magnets (4, M1-M6), and an (actuator 16) to impart relative motion between the permanent magnets and the apertures (6) to switch between a first configuration and a second configuration. For a given aperture (6): in one of the first configuration and the second configuration, one of the permanent magnets is positioned adjacent to the first side of the aperture, in the other of the first configuration and the second configuration, a different one of the permanent magnets is positioned adjacent to the second side of the aperture. This is useful for many lab experiments involving magnetic beads placed in receptacles.

Methods of treatment of inflammatory diseases

Methods of treatment of inflammatory diseases

Thymic constucts and uses thereof

Thymic constructs and uses thereof

The present invention provides a method of producing a thymic construct suitable for implantation into a subject, the method comprising the steps of: (i) providing an acellular scaffold; (ii) seeding the acellular scaffold with thymic epithelial cells having mesenchymal properties; and (iii) culturing the seeded scaffold to produce said construct. The thymic epithelial cells are preferably CD49f+ and may also be VIM+, TE-7+ and/or CD90+. The invention further provides pharmaceutical compositions, uses and therapies using thymic epithelial cells having mesenchymal properties.

使用数字疗法治疗抑郁症的系统和方法

经由数字疗法治疗抑郁症的系统和方法。数字疗法可以被配置为根据时间表提供记忆任务练习并根据另一个时间表提供心理治疗课程。心理治疗课程可以包括被配置为通过情感调节、行为激活和认知重建中的至少一种来提供疗法干预的动画视频。这两个时间表可以限定六周的治疗期。记忆任务练习可以包括情感面部记忆任务(EFMT)练习，并且心理治疗课程可以包括认知行为治疗(CBT)课程。

Electrochemical wire electrode array and corresponding fabrication process

An electrochemical probe (2) comprises a wire bundle including two or more wire electrodes made of conducting material (6) arranged alongside each other, and insulating material (8) surrounding the electrodes. An impedance reducing layer of metal or metal oxide nano-structures is deposited on tips of the wire electrodes at a first end of the bundle, preferably in a recess. A functionalization layer is deposited on the impedance reducing layer at the first end of the bundle. Such a probe is particularly useful for electrochemical sensing applications such as neuronal scanning.

Sicherheitsgerät

Immunoconjugate

Immunoconjugate

Methods of treatment of intestinal infections

The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and methods for treating or preventing viral or bacterial infections, in particular intestinal infections such as those caused by rotavirus and Salmonella spp. Infections. The methods comprise administration of, and the compositions comprise, a farnesyl-diphosphate farnesyltransferase 1 (FDFT1) inhibitor, such as lapaquistat.

Determination of lymphocyte abundance in mixed samples

Methods for determining the fraction of lymphocytes in a mixed sample comprising genomic material from multiple cell types are described. The methods comprise obtaining a read depth profile for the sample along a predetermined genomic region of interest including at least a portion of a genomic locus that undergoes VDJ recombination; obtaining a plurality of read depth ratios (ri) by normalising the read depths by reference to a baseline read depth derived from a subset of the region of interest; obtaining a summarised read depth ratio value (rVDJ) for a subset of the region of interest that is likely to be deleted through VDJ recombination; and determining the fraction of lymphocytes (f) in the sample as a function of the summarised read depth ratio value (rVDJ). Methods of providing a diagnosis or prognosis based on the lymphocyte fraction are also described, as well as related systems and products.

Methods of treatment of melanocytic disease

Provided herein are novel compositions and methods for treating melanocytic disease. Provided herein are novel compositions and methods of treating diseases arising from gain-of-function NRAS and BRAF variants including cancer, in particular melanoma, as well as congenital melanocytic naevi (CMN) and acquired melanocytic naevi (AMN).

Methods of treatment of GNAQ and GNA11 driven disease

Methods of treatment of gnaq and gna11 mosaicism

确保使用数字疗法的疾病和障碍的治疗中的数据安全性的系统和方法

本公开涉及确保使用数字疗法的疾病和障碍的治疗中的数据安全性的系统和方法。方法包括通过网络从与具有用于治疗潜在疾病或障碍的激活的数字治疗处方的患者相关联的患者设备接收患者生成的事件数据。患者生成的事件数据由患者设备加密，并且包括与激活的数字治疗处方相关的至少一个带时间戳的事件。响应于接收到患者生成的事件数据，该方法包括解密、匿名化和将匿名化的患者生成的事件数据存储在存储器硬件上。该方法还包括通过网络从医疗保健提供者(HCP)系统接收请求患者生成的事件数据并包括认证令牌的患者记录请求。响应于接收到该患者记录请求，该方法包括使用认证令牌从存储器硬件检索和加密匿名化的患者生成的事件数据。

电化学导线电极阵列及相应制造过程

电化学探针(2)包括具有彼此并排布置的由导电材料(6)制成的两个或多个导线电极的导线束，以及包围电极的绝缘材料(8)。金属或金属氧化物纳米结构的阻抗减小层在导线束的第一端处沉积在导线电极的尖端上。功能化层在导线束的第一端处沉积在阻抗减小层上。这种探针特别适用于诸如神经元扫描的电化学感测应用。

Novel cancer antigens and methods

Novel cancer antigens and methods

Targets for cancer therapy

The present invention relates to solute carrier proteins as targets for cancer therapy. In particular, it relates to the inhibition of serine transport by two or more solute carrier proteins. The compositions, uses and methods of the present invention have utility in the treatment of cancer.

游离前列腺特异抗原与总前列腺特异抗原一体化酶联免疫检测试剂盒及检测方法

本发明公开一种游离前列腺特异抗原与总前列腺特异抗原检测一体化酶联免疫检测试剂盒及检测方法。本发明主要包括链霉亲和素包被酶标反应板，生物素标记抗总PSA单克隆抗体，生物素标记抗游离PSA单克隆抗体，酶标记抗PSA多克隆抗体，洗涤缓冲液，显色液，终止液，质控血清。本发明不直接将捕获抗体包被在酶标反应板上，克服了试剂盒受到多种因素干扰酶活性的缺陷。而是利用生物素-亲和素系统于包被工艺，制备成链霉亲和素包被的酶标反应板，捕获生物素标记抗体，形成稳定复合物。在同一酶标反应板上完成两种抗原的检测，直接获取f-PSA/t-PSA的比值，不仅提高测定准确性，并且缩短测定时间、简化测定流程、降低测定成本、效率提高。

Method, solution and kit for preparing a tissue sample for 3d imaging

The present invention relates to a solution for the preparation of a tissue sample for the purpose of three dimensional (3D) imaging The invention also relates to methods and uses involving the solution.

Determination of lymphocyte abundance in mixed samples

Methods for determining the fraction of lymphocytes in a mixed sample comprising genomic material from multiple cell types are described. The methods comprise obtaining a read depth profile for the sample along a predetermined genomic region of interest including at least a portion of a genomic locus that undergoes VDJ recombination; obtaining a plurality of read depth ratios (ri) by normalising the read depths by reference to a baseline read depth derived from a subset of the region of interest; obtaining a summarised read depth ratio value (rVDJ) for a subset of the region of interest that is likely to be deleted through VDJ recombination; and determining the fraction of lymphocytes (f) in the sample as a function of the summarised read depth ratio value (rVDJ). Methods of providing a diagnosis or prognosis based on the lymphocyte fraction are also described, as well as related systems and products.

Determination of lymphocyte abundance in mixed samples

Methods for determining the fraction of lymphocytes in a mixed sample comprising genomic material from multiple cell types are described. The methods comprise obtaining a read depth profile for the sample along a predetermined genomic region of interest including at least a portion of a genomic locus that undergoes VDJ recombination; obtaining a plurality of read depth ratios (ri) by normalising the read depths by reference to a baseline read depth derived from a subset of the region of interest; obtaining a summarised read depth ratio value (rVDJ) for a subset of the region of interest that is likely to be deleted through VDJ recombination; and determining the fraction of lymphocytes (f) in the sample as a function of the summarised read depth ratio value (rVDJ). Methods of providing a diagnosis or prognosis based on the lymphocyte fraction are also described, as well as related systems and products.

Determination of lymphocyte abundance in mixed samples

Determination of lymphocyte abundance in mixed samples